EXPLORE!

EMA Approves Dasiglucagon for Severe Hypoglycemia Management in Diabetes

  426 Views

Emedinexus     21 November 2024

The European Medicines Agency (EMA) has granted approval for dasiglucagon in 2024, providing a new therapeutic option for the treatment of severe hypoglycemia in diabetes patients. Dasiglucagon, a novel rescue therapy, is formulated to rapidly elevate blood glucose levels during severe hypoglycemic episodes, which can lead to confusion, seizures, unconsciousness, and, in extreme cases, death if not treated promptly. This approval marks a significant advancement in emergency management for diabetic patients, offering a fast-acting and effective solution to prevent life-threatening complications associated with dangerously low blood sugar levels.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.